985P Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)Ahmed O. Kaseb, Laura E. Crotty Alexander, M. Karkhanis et al.|Annals of Oncology|2024Cited by 1